Exploring pharmacological approaches for managing cytokine storm associated with pneumonia and acute respiratory distress syndrome in COVID-19 patients

Exploring pharmacological approaches for managing cytokine storm associated with pneumonia and acute respiratory distress syndrome in COVID-19 patients

Abstract Sars-CoV-2 complications include pneumonia and acute respiratory distress syndrome (ARDS), which require intensive care unit admission. These conditions have rapidly overwhelmed healthcare systems, with detrimental effects on the quality of care and increased mortality. Social isolation str...

Full description

Bibliographic Details
Main Authors: Irma Convertino, Marco Tuccori, Sara Ferraro, Giulia Valdiserra, Emiliano Cappello, Daniele Focosi, Corrado Blandizzi
Format: Article
Language:English
Published: BMC 2020-06-01
Series:Critical Care
Subjects:
Sars-CoV-2
COVID-19
Cytokines
Interleukin-6
Tumor necrosis factor
Janus kinases
Online Access:http://link.springer.com/article/10.1186/s13054-020-03020-3
id doaj-30b88a3c1ac94c50b62924fc08020826
record_format Article
spelling doaj-30b88a3c1ac94c50b62924fc080208262020-11-25T03:54:25ZengBMCCritical Care1364-85352020-06-012411610.1186/s13054-020-03020-3Exploring pharmacological approaches for managing cytokine storm associated with pneumonia and acute respiratory distress syndrome in COVID-19 patientsIrma Convertino0Marco Tuccori1Sara Ferraro2Giulia Valdiserra3Emiliano Cappello4Daniele Focosi5Corrado Blandizzi6Unit of Pharmacology and Pharmacovigilance, Department of Clinical and Experimental Medicine, University of PisaUnit of Pharmacology and Pharmacovigilance, Department of Clinical and Experimental Medicine, University of PisaUnit of Pharmacology and Pharmacovigilance, Department of Clinical and Experimental Medicine, University of PisaUnit of Pharmacology and Pharmacovigilance, Department of Clinical and Experimental Medicine, University of PisaUnit of Pharmacology and Pharmacovigilance, Department of Clinical and Experimental Medicine, University of PisaNorth-Western Tuscany Blood Bank, Pisa University HospitalUnit of Pharmacology and Pharmacovigilance, Department of Clinical and Experimental Medicine, University of PisaAbstract Sars-CoV-2 complications include pneumonia and acute respiratory distress syndrome (ARDS), which require intensive care unit admission. These conditions have rapidly overwhelmed healthcare systems, with detrimental effects on the quality of care and increased mortality. Social isolation strategies have been implemented worldwide with the aim of reducing hospital pressure. Among therapeutic strategies, the use of immunomodulating drugs, to improve prognosis, seems promising. Particularly, since pneumonia and ARDS are associated with a cytokine storm, drugs belonging to therapeutic classes as anti-IL-6, anti-TNF, and JAK inhibitors are currently studied. In this article, we discuss the potential advantages of the most promising pharmacological approaches.http://link.springer.com/article/10.1186/s13054-020-03020-3Sars-CoV-2COVID-19CytokinesInterleukin-6Tumor necrosis factorJanus kinases
collection DOAJ
language English
format Article
sources DOAJ
author Irma Convertino
Marco Tuccori
Sara Ferraro
Giulia Valdiserra
Emiliano Cappello
Daniele Focosi
Corrado Blandizzi
spellingShingle Irma Convertino
Marco Tuccori
Sara Ferraro
Giulia Valdiserra
Emiliano Cappello
Daniele Focosi
Corrado Blandizzi
Exploring pharmacological approaches for managing cytokine storm associated with pneumonia and acute respiratory distress syndrome in COVID-19 patients
Critical Care
Sars-CoV-2
COVID-19
Cytokines
Interleukin-6
Tumor necrosis factor
Janus kinases
author_facet Irma Convertino
Marco Tuccori
Sara Ferraro
Giulia Valdiserra
Emiliano Cappello
Daniele Focosi
Corrado Blandizzi
author_sort Irma Convertino
title Exploring pharmacological approaches for managing cytokine storm associated with pneumonia and acute respiratory distress syndrome in COVID-19 patients
title_short Exploring pharmacological approaches for managing cytokine storm associated with pneumonia and acute respiratory distress syndrome in COVID-19 patients
title_full Exploring pharmacological approaches for managing cytokine storm associated with pneumonia and acute respiratory distress syndrome in COVID-19 patients
title_fullStr Exploring pharmacological approaches for managing cytokine storm associated with pneumonia and acute respiratory distress syndrome in COVID-19 patients
title_full_unstemmed Exploring pharmacological approaches for managing cytokine storm associated with pneumonia and acute respiratory distress syndrome in COVID-19 patients
title_sort exploring pharmacological approaches for managing cytokine storm associated with pneumonia and acute respiratory distress syndrome in covid-19 patients
publisher BMC
series Critical Care
issn 1364-8535
publishDate 2020-06-01
description Abstract Sars-CoV-2 complications include pneumonia and acute respiratory distress syndrome (ARDS), which require intensive care unit admission. These conditions have rapidly overwhelmed healthcare systems, with detrimental effects on the quality of care and increased mortality. Social isolation strategies have been implemented worldwide with the aim of reducing hospital pressure. Among therapeutic strategies, the use of immunomodulating drugs, to improve prognosis, seems promising. Particularly, since pneumonia and ARDS are associated with a cytokine storm, drugs belonging to therapeutic classes as anti-IL-6, anti-TNF, and JAK inhibitors are currently studied. In this article, we discuss the potential advantages of the most promising pharmacological approaches.
topic Sars-CoV-2
COVID-19
Cytokines
Interleukin-6
Tumor necrosis factor
Janus kinases
url http://link.springer.com/article/10.1186/s13054-020-03020-3
work_keys_str_mv AT irmaconvertino exploringpharmacologicalapproachesformanagingcytokinestormassociatedwithpneumoniaandacuterespiratorydistresssyndromeincovid19patients
AT marcotuccori exploringpharmacologicalapproachesformanagingcytokinestormassociatedwithpneumoniaandacuterespiratorydistresssyndromeincovid19patients
AT saraferraro exploringpharmacologicalapproachesformanagingcytokinestormassociatedwithpneumoniaandacuterespiratorydistresssyndromeincovid19patients
AT giuliavaldiserra exploringpharmacologicalapproachesformanagingcytokinestormassociatedwithpneumoniaandacuterespiratorydistresssyndromeincovid19patients
AT emilianocappello exploringpharmacologicalapproachesformanagingcytokinestormassociatedwithpneumoniaandacuterespiratorydistresssyndromeincovid19patients
AT danielefocosi exploringpharmacologicalapproachesformanagingcytokinestormassociatedwithpneumoniaandacuterespiratorydistresssyndromeincovid19patients
AT corradoblandizzi exploringpharmacologicalapproachesformanagingcytokinestormassociatedwithpneumoniaandacuterespiratorydistresssyndromeincovid19patients
_version_ 1724473703163494400

Similar Items